<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645306</url>
  </required_header>
  <id_info>
    <org_study_id>Revacept/CS/02</org_study_id>
    <nct_id>NCT01645306</nct_id>
  </id_info>
  <brief_title>Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)</brief_title>
  <acronym>Revacept/CS/02</acronym>
  <official_title>Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdvanceCor GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AdvanceCor GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks
      (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet
      monotherapy or monotherapy alone.

      Patients receive a single dose of trial medication by intravenous infusion for 20 minutes.
      Patients are followed up one and three days after treatment, at 3 months and by a telephone
      interview at 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of incidence of microembolic signals (MES)</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>In patients with symptomatic carotid artery stenosis who have been treated with Revacept plus antiplatelet monotherapy versus antiplatelet monotherapy alone (placebo). MES will be assessed by transcranial Doppler (TCD) examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in rate of MES per hour</measure>
    <time_frame>24 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of neurological status (NIH Stroke Scale)</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral lesion analysis by DWI-NMR</measure>
    <time_frame>1 day after CEA / intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoint rate of all cause death</measure>
    <time_frame>up to 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiovascular outcome</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>myocardial infarction and re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>up to 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG parameters</measure>
    <time_frame>up to 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of anti-drug antibody titres</measure>
    <time_frame>up to 3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>up to 3 months after treatment</time_frame>
    <description>including wound healing complications, laboratory abnormalities and use of concomitant medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Where feasible: Assessment of Haemostasis Safety</measure>
    <time_frame>up to 3 months after treatment</time_frame>
    <description>laboratory parameters indicating thrombocytopenia and bleeding according to the RE-LY study group criteria, in vitro platelet function, in vitro bleeding time by PFA-100 / PFA-200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoint rate of stroke-related death</measure>
    <time_frame>up to 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoint TIA, amaurosis fugax or stroke including haemorrhagic stroke</measure>
    <time_frame>up to 12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carotid Stenosis</condition>
  <condition>Atherosclerosis</condition>
  <condition>Stroke</condition>
  <condition>Transient-ischaemic Attack</condition>
  <condition>TIA</condition>
  <condition>Amaurosis Fugax</condition>
  <arm_group>
    <arm_group_label>Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg Revacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg Revacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revacept</intervention_name>
    <description>single intravenous injection</description>
    <arm_group_label>40 mg Revacept</arm_group_label>
    <arm_group_label>120 mg Revacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single intravenous injection</description>
    <arm_group_label>Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Target population

               -  Diagnosis:

                    -  Extracranial carotid artery stenosis (diagnosed by vascular duplex
                       ultrasound peak flow or angiography)

                    -  Lesions with ≥ 50 % stenosis according to the European Carotid Surgery Trial
                       (ECST) criteria

                    -  TIA, amaurosis fugax or stroke within the last 30 days

               -  Age and sex: Men and women aged &gt; 18 years Women of childbearing potential
                  (WOCBP) must be using an adequate method of contraception to avoid pregnancy
                  throughout the study and for up to 4 weeks after receiving investigational
                  product in such a manner that the risk of pregnancy is minimised.

        Exclusion Criteria:

          1. Sex and reproductive Status:

               -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy
                  for up to 4 weeks after receiving investigational product.

               -  Women who are pregnant or breastfeeding

               -  Women with a positive pregnancy test on enrollment or prior to investigational
                  product administration.

          2. Target disease exceptions

               -  NIHSS score &gt; 18

               -  Recent intracerebral haemorrhage by X-ray computed tomography (CT) or nuclear
                  magnetic resonance (NMR)

               -  Cardiac cause of embolisation (atrial fibrillation or other cardiac source e.g.
                  artificial heart valves)

          3. Medical history and concurrent disease

               -  History of hypersensitivity, contraindication or serious adverse reaction to
                  inhibitors of platelet aggregation, hypersensitivity to related drugs
                  (cross-allergy) or to any of the excipients in the study drug

               -  History or evidence of thrombocytopenia (&lt;30.000/ul), bleeding diathesis or
                  coagulopathy (pathological international normalised ratio (INR) or activated
                  partial thromboplastin time (aPTT))

               -  Thrombolysis within the last 48 hours

               -  Relevant haemorrhagic transformation as determined by CT, NMR or anamnesis

               -  Oral anticoagulation or dual anti-platelet therapy with aspirin or clopidogrel
                  and other P2Y inhibitors at screening (3 days for dipyridamole extended release;
                  8 hours for tirofiban/Aggrastat)

               -  Sustained hypertension (systolic BP &gt; 179 mmHg or diastolic BP &gt;109 mmHg)

               -  History of severe systemic disease such as terminal carcinoma, renal failure (or
                  current creatinine &gt; 200 umol/l), cirrhosis, severe dementia, or psychosis

               -  Current severe liver dysfunction (transaminase level greater than 5-fold over
                  upper normal range limit)

               -  Active autoimmune disorder such as systemic lupus erythematosus, rheumatoid
                  arthritis, vasculitis or glomerulonephritis

               -  Known atrial fibrillation or other clinically significant ECG abnormalities (at
                  present)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Poppert, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, TU Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian M Loftus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Poppert, PD Dr. med.</last_name>
    <phone>004989-4140</phone>
    <phone_ext>4606</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Site 01: Department of Neurology, TU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Poppert, PD Dr. med.</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>4606</phone_ext>
    </contact>
    <investigator>
      <last_name>Holger Poppert, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 08: Universitätsklinikum Essen, Klinik für Neurologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Dietzold</last_name>
    </contact>
    <investigator>
      <last_name>Christian Weimar, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 11: Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Otto</last_name>
    </contact>
    <contact_backup>
      <last_name>Kirsten Jaramillo</last_name>
    </contact_backup>
    <investigator>
      <last_name>Götz Thomalla, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Golsari, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 07: Medizinische Hochschule Hannover, Klinik für Neurologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Worthmann, Dr. med.</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>3580</phone_ext>
    </contact>
    <investigator>
      <last_name>Karin Weißenborn, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Worthmann, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 12: Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Urban</last_name>
    </contact>
    <contact_backup>
      <last_name>Rita Lachmund</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dominik Michalski, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 09: Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Gröschel, PD Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Gröschel, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Uphaus</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 04: Universitätsklinikum Tübingen, Klinik für Allgemeine Neurologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Poli, Dr. med.</last_name>
      <phone>07071 29</phone>
      <phone_ext>84427</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Julia Zeller</last_name>
    </contact_backup>
    <investigator>
      <last_name>Sven Poli, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziemann Ulf, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 06: Universitätsklinikum Ulm, Abteilung für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Raubold</last_name>
      <phone>+49 731 177</phone>
      <phone_ext>5721</phone_ext>
    </contact>
    <investigator>
      <last_name>Hermann Neugebauer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Knauer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 23 - University Hospital Coventry NHS Trust</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Imray, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chris Imray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 26 - University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Richards, MD</last_name>
    </contact>
    <investigator>
      <last_name>Toby Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 28 - King's College London Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Rashid</last_name>
    </contact>
    <investigator>
      <last_name>Hisham Rashid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site 20: St George's NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian M Loftus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bültmann A, Li Z, Wagner S, Peluso M, Schönberger T, Weis C, Konrad I, Stellos K, Massberg S, Nieswandt B, Gawaz M, Ungerer M, Münch G. Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. J Mol Cell Cardiol. 2010 Sep;49(3):532-42. doi: 10.1016/j.yjmcc.2010.04.009. Epub 2010 Apr 27.</citation>
    <PMID>20430036</PMID>
  </reference>
  <reference>
    <citation>Goertler M, Baeumer M, Kross R, Blaser T, Lutze G, Jost S, Wallesch CW. Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. Stroke. 1999 Jan;30(1):66-9.</citation>
    <PMID>9880390</PMID>
  </reference>
  <reference>
    <citation>Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005 May 3;111(17):2233-40. Epub 2005 Apr 25.</citation>
    <PMID>15851601</PMID>
  </reference>
  <reference>
    <citation>Massberg S, Konrad I, Bültmann A, Schulz C, Münch G, Peluso M, Lorenz M, Schneider S, Besta F, Müller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M, Gawaz M. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004 Feb;18(2):397-9. Epub 2003 Dec 4.</citation>
    <PMID>14656994</PMID>
  </reference>
  <reference>
    <citation>Molloy J, Markus HS. Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. Stroke. 1999 Jul;30(7):1440-3.</citation>
    <PMID>10390320</PMID>
  </reference>
  <reference>
    <citation>Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003 Jul 15;102(2):449-61. Epub 2003 Mar 20. Review.</citation>
    <PMID>12649139</PMID>
  </reference>
  <reference>
    <citation>Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, Markus HS, Russell D, Siebler M. Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. Stroke. 1998 Mar;29(3):725-9.</citation>
    <PMID>9506619</PMID>
  </reference>
  <reference>
    <citation>Schönberger T, Siegel-Axel D, Bussl R, Richter S, Judenhofer MS, Haubner R, Reischl G, Klingel K, Münch G, Seizer P, Pichler BJ, Gawaz M. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice. Cardiovasc Res. 2008 Oct 1;80(1):131-7. doi: 10.1093/cvr/cvn169. Epub 2008 Jun 19.</citation>
    <PMID>18566102</PMID>
  </reference>
  <reference>
    <citation>Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Münch G. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011 May 3;123(17):1891-9. doi: 10.1161/CIRCULATIONAHA.110.980623. Epub 2011 Apr 18.</citation>
    <PMID>21502572</PMID>
  </reference>
  <reference>
    <citation>Jamasbi J, Megens RT, Bianchini M, Münch G, Ungerer M, Faussner A, Sherman S, Walker A, Goyal P, Jung S, Brandl R, Weber C, Lorenz R, Farndale R, Elia N, Siess W. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies. J Am Coll Cardiol. 2015 Jun 9;65(22):2404-15. doi: 10.1016/j.jacc.2015.03.573.</citation>
    <PMID>26046734</PMID>
  </reference>
  <reference>
    <citation>Kleiman NS, Kolandaivelu K. Expanding the Roster: Developing New Inhibitors of Intravascular Thrombosis. J Am Coll Cardiol. 2015 Jun 9;65(22):2416-9. doi: 10.1016/j.jacc.2015.03.576.</citation>
    <PMID>26046735</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Amaurosis Fugax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

